Want to see PRQR full AI Analyst Report?
PRQR Stock Chart & Stats
$2.38
$0.01(0.58%)
At close: 4:00 PM EDT
$2.38
$0.01(0.58%)
Day’s Range― - ―
52-Week Range$1.33 - $3.10
Previous Close$1.7
Volume683.10K
Average Volume (3M)878.33K
Market Cap
$296.89M
Enterprise Value$85.70
Total Cash (Recent Filing)$117.08M
Total Debt (Recent Filing)$13.19M
Price to Earnings (P/E)―
Beta2.18
Next Earnings
Nov 05, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding138,087,650
10 Day Avg. Volume1,156,392
30 Day Avg. Volume878,328
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)3.12
Price to Sales (P/S)11.85
P/FCF Ratio-3.37
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.57Price Target Upside260.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.42
Revenue Forecast (FY)$15.71M
Bulls Say, Bears Say
Bulls Say
Axiomer Clinical ValidationPositive Phase 1 biomarker and safety results provide initial human validation for Axiomer RNA editing. This may improve confidence in the platform, support advancement of AX-0811 and strengthen ProQR’s ability to attract partners.
Cash Runway StrengthenedThe equity raise and increased cash balance provide funding visibility for clinical development and reduce near-term financing pressure. A longer runway allows ProQR to pursue milestones that could improve partnership and strategic value.
Revenue Rebound And High Gross MarginsImproving revenue and very high gross margins indicate that collaboration-related income can scale efficiently when milestones or research payments occur. This supports the platform’s economic potential, although it has not yet translated into profitability.
Bears Say
Deep Ongoing LossesProQR remains materially distant from break-even despite revenue growth. Persistent operating losses could consume equity and increase dependence on future financing, limiting strategic flexibility until clinical programs generate milestones or commercial revenue.
Structural Cash BurnContinued negative operating and free cash flow shows that current activities do not fund research and development. If development spending remains elevated, ProQR may need additional capital before products or partnerships can provide self-sustaining cash generation.
Clinical-stage Revenue DependenceWithout approved products and recurring sales, financial performance remains dependent on collaboration payments, milestones and external financing. Delays or unsuccessful trials could reduce partner income and extend the period before the business achieves durable revenue.
ProQR News
PRQR FAQ
What was ProQR’s price range in the past 12 months?
ProQR lowest stock price was $1.33 and its highest was $3.10 in the past 12 months.
What is ProQR’s market cap?
ProQR’s market cap is $296.89M.
When is ProQR’s upcoming earnings report date?
ProQR’s upcoming earnings report date is Nov 05, 2026 which is in 61 days.
How were ProQR’s earnings last quarter?
ProQR released its earnings results on Aug 13, 2026. The company reported -$0.093 earnings per share for the quarter, beating the consensus estimate of -$0.133 by $0.04.
Is ProQR overvalued?
According to Wall Street analysts ProQR’s price is currently Undervalued.
Does ProQR pay dividends?
ProQR does not currently pay dividends.
What is ProQR’s EPS estimate?
ProQR’s EPS estimate is -0.12.
How many shares outstanding does ProQR have?
ProQR has 138,087,650 shares outstanding.
What happened to ProQR’s price movement after its last earnings report?
ProQR reported an EPS of -$0.093 in its last earnings report, beating expectations of -$0.133. Following the earnings report the stock price went down -0.538%.
Which hedge fund is a major shareholder of ProQR?
Currently, no hedge funds are holding shares in PRQR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProQR Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.57 (260.14% Upside)
$8.57 (260.14% Upside)
Blogger Sentiment
Bullish
PRQR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 13.7%
Last 30 Days ▲ 13.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.99%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-5.42%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
ProQR
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
PRQR Stock 12 Month Forecast
Average Price Target
$8.57
▲(260.14% Upside)
Technical Analysis
Ownership Overview
0.58% Insiders
1.41% Mutual Funds
31.29% Other Institutional Investors
66.44% Public Companies and
Individual Investors